Skip to the comparison

Medicare GLP-1 Bridge: $50 a month, and the rules behind it

Medicare GLP-1 Bridge from 1 Jul 2026 to 31 Dec 2027

Primary source

Not a news summary

Everything on this page is taken from the program's own documentation. Read it yourself before making a decision. Eligibility and formulary rules change, and this page is not insurance advice.

Medicare GLP-1 Bridge on cms.gov (opens in a new tab)

We track prices, terms and availability. We are not clinicians, this page is not medically reviewed, and nothing here is medical advice. Talk to a licensed clinician about whether a GLP-1 medication is right for you.

What the program is

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. Eligible beneficiaries will have a $50 copay.

CMS 13 Jul 2026 Primary source (opens in a new tab)

It is a demonstration, not a change to your Part D plan. Pharmacies send Bridge claims to a central processor CMS set up, not to your plan. You need Part D coverage to use it, and you need a prescriber willing to fill in a prior authorization form. The CMS fact sheet (No. 12234, June 2026) describes no separate sign-up step for you: the route runs through your prescriber and your pharmacy.

Three drugs are covered: Foundayo tablets, Wegovy as an injection or a tablet, and Zepbound in the KwikPen only. The full list, and what is not on it, is on our covered drugs page.

The $50, and what it does not count toward

The Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary's TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries.

CMS 13 Jul 2026 Primary source (opens in a new tab)

Four things follow from that. You pay $50 from the first fill, because the deductible does not apply. That $50 does not move you toward your plan's yearly out-of-pocket limit. Extra Help does not lower it: the CMS fact sheet (No. 12234, June 2026) says the cost is $50 a month "no matter your income level". And the same fact sheet says these drugs are not eligible for the Medicare Prescription Payment Plan.

Each fill is one month. CMS's pharmacy guidance says a fill is a single 28- or 30-day supply, and that 60- or 90-day fills are not available.

Beneficiaries who are approved for coverage under the Medicare GLP-1 Bridge may obtain a single monthly supply (28 or 30 days) of an eligible GLP-1 product per fill. Sixty or ninety-day fills are not available.

CMS 17 Aug 2026 Primary source (opens in a new tab)

Who qualifies, and how you get it

There are four requirements: Part D coverage through an eligible plan type, no GLP-1 already paid for by that plan, none of three excluded diagnoses, and an age and BMI threshold. Each is set out with CMS's wording on our eligibility page. Whether you meet the clinical part is your prescriber's call, not ours.

Getting it takes a prescription, a pharmacy claim and a prior authorization your prescriber submits after the pharmacy asks. CMS says the decision comes within 72 hours. The steps, and what happens after a denial, are on how to get a GLP-1 through the Bridge.

If you pay cash through a telehealth provider now

This site tracks cash prices at telehealth providers, and most of the programs we list sell compounded semaglutide or tirzepatide. The Bridge covers none of those. Its list names three branded products and nothing else.

If you are on Medicare, have Part D and qualify, compare the $50 with what you pay now. Our Wegovy cost guide has the cash prices we track, each with the date we read it.

On the prescriber, CMS says a provider does not need to be enrolled in Medicare to write the prescription or submit the prior authorization, but must not be on Medicare's Preclusion List. CMS's guidance does not mention telehealth either way. Whether a particular telehealth company will complete the Bridge form for you is its decision, and we have not established which ones do.

For the Medicare GLP-1 Bridge, as in the Part D program, a provider does not need to be enrolled in Medicare to write a prescription or submit a prior authorization request. However, the provider must not be on the Preclusion List for the drug to be coverable.

CMS 6 Aug 2026 Primary source (opens in a new tab)

Questions readers ask

What happens to the Bridge after December 2027?

CMS has not said it continues. Its program page says the Bridge lets CMS collect data on GLP-1 use to share with Part D plans "ahead of potential implementation of BALANCE in Part D". Potential is CMS's word. We will update this page if CMS announces what follows it.

Is there a form I fill in to join?

Not in CMS's beneficiary material. The fact sheet's steps are: talk to your prescriber, the prescription goes to a pharmacy, your prescriber submits the approval form, and Medicare sends you a letter when the drug is covered.

Who do I call with a question about my own case?

CMS directs beneficiaries to 1-800-MEDICARE (1-800-633-4227), TTY 1-877-486-2048. We cannot look up your plan or your approval.

More on the Medicare GLP-1 Bridge

How this site works

How we rate providers

Ratings weigh verified price, total first-year cost, state availability, speed to prescription, cancellation terms and regulatory record. Full scoring rubric.

No clinical review

We are not clinicians and this page carries no clinical review. Drug and regulatory facts are cited directly from FDA, CMS and court records, never a provider's marketing claims.

How we make money

When you sign up with a provider through our links, we may earn a referral fee. Fees never influence a rating, a price, or a position in a table. Full advertiser disclosure.